Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 299

1.

Molecular Comparison of Imatinib-Naïve and Resistant Gastrointestinal Stromal Tumors: Differentially Expressed microRNAs and mRNAs.

Amirnasr A, Gits CMM, van Kuijk PF, Smid M, Vriends ALM, Rutkowski P, Sciot R, Schöffski P, Debiec-Rychter M, Sleijfer S, Wiemer EAC.

Cancers (Basel). 2019 Jun 24;11(6). pii: E882. doi: 10.3390/cancers11060882.

2.

Anti-tumor activity of the MDM2-TP53 inhibitor BI-907828 in dedifferentiated liposarcoma patient-derived xenograft models harboring MDM2 amplification.

Cornillie J, Wozniak A, Li H, Gebreyohannes YK, Wellens J, Hompes D, Debiec-Rychter M, Sciot R, Schöffski P.

Clin Transl Oncol. 2019 Jun 14. doi: 10.1007/s12094-019-02158-z. [Epub ahead of print]

PMID:
31201607
3.

Retrospective Analysis of Patients with Advanced Liposarcoma in a Tertiary Referral Center.

Langmans C, Cornillie J, van Cann T, Wozniak A, Hompes D, Sciot R, Debiec-Rychter M, Vandenbempt I, Schöffski P.

Oncol Res Treat. 2019 Jun 6:1-8. doi: 10.1159/000500608. [Epub ahead of print]

PMID:
31170709
4.

Establishment and Characterization of Histologically and Molecularly Stable Soft-tissue Sarcoma Xenograft Models for Biological Studies and Preclinical Drug Testing.

Cornillie J, Wozniak A, Li H, Wang Y, Boeckx B, Gebreyohannes YK, Wellens J, Vanleeuw U, Hompes D, Stas M, Sinnaeve F, Wafa H, Lambrechts D, Debiec-Rychter M, Sciot R, Schöffski P.

Mol Cancer Ther. 2019 Jun;18(6):1168-1178. doi: 10.1158/1535-7163.MCT-18-1045. Epub 2019 Apr 8.

PMID:
30962320
5.

Genomic aberrations in cell cycle genes predict progression of KIT-mutant gastrointestinal stromal tumors (GISTs).

Heinrich MC, Patterson J, Beadling C, Wang Y, Debiec-Rychter M, Dewaele B, Corless CL, Duensing A, Raut CP, Rubin B, Ordog T, van de Rijn M, Call J, Mühlenberg T, Fletcher JA, Bauer S.

Clin Sarcoma Res. 2019 Mar 5;9:3. doi: 10.1186/s13569-019-0112-7. eCollection 2019.

6.

A Case of Undifferentiated Sarcoma in the Superior Vena Cava and Bilateral Cervical Veins.

Kobayashi H, Kobayashi Y, Yuasa S, Okabe M, Yamada Y, Oda Y, Debiec-Rychter M, Rubin BP, Suzuki T.

Am J Case Rep. 2018 Dec 19;19:1507-1514. doi: 10.12659/AJCR.911659.

7.

PLX9486 shows anti-tumor efficacy in patient-derived, tyrosine kinase inhibitor-resistant KIT-mutant xenograft models of gastrointestinal stromal tumors.

Gebreyohannes YK, Burton EA, Wozniak A, Matusow B, Habets G, Wellens J, Cornillie J, Lin J, Nespi M, Wu G, Zhang C, Bollag G, Debiec-Rychter M, Sciot R, Schöffski P.

Clin Exp Med. 2019 May;19(2):201-210. doi: 10.1007/s10238-018-0541-2. Epub 2018 Dec 6.

PMID:
30523507
8.

Discovery and Characterization of Recurrent, Targetable ALK Fusions in Leiomyosarcoma.

Davis LE, Nusser KD, Przybyl J, Pittsenbarger J, Hofmann NE, Varma S, Vennam S, Debiec-Rychter M, van de Rijn M, Davare MA.

Mol Cancer Res. 2019 Mar;17(3):676-685. doi: 10.1158/1541-7786.MCR-18-1075. Epub 2018 Dec 5.

PMID:
30518629
9.

Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors.

Gebreyohannes YK, Wozniak A, Zhai ME, Wellens J, Cornillie J, Vanleeuw U, Evans E, Gardino AK, Lengauer C, Debiec-Rychter M, Sciot R, Schöffski P.

Clin Cancer Res. 2019 Jan 15;25(2):609-618. doi: 10.1158/1078-0432.CCR-18-1858. Epub 2018 Oct 1.

PMID:
30274985
10.

Clear Cell Odontogenic Carcinoma: Occurrence of EWSR1-CREB1 as Alternative Fusion Gene to EWSR1-ATF1.

Vogels R, Baumhoer D, van Gorp J, Eijkelenboom A, Verdijk M, van Cleef P, Bloemena E, Slootweg PJ, Lohman B, Debiec-Rychter M, Flucke U.

Head Neck Pathol. 2019 Jun;13(2):225-230. doi: 10.1007/s12105-018-0953-z. Epub 2018 Jul 25.

PMID:
30047065
11.

Toward Minimal Residual Disease-Directed Therapy in Melanoma.

Rambow F, Rogiers A, Marin-Bejar O, Aibar S, Femel J, Dewaele M, Karras P, Brown D, Chang YH, Debiec-Rychter M, Adriaens C, Radaelli E, Wolter P, Bechter O, Dummer R, Levesque M, Piris A, Frederick DT, Boland G, Flaherty KT, van den Oord J, Voet T, Aerts S, Lund AW, Marine JC.

Cell. 2018 Aug 9;174(4):843-855.e19. doi: 10.1016/j.cell.2018.06.025. Epub 2018 Jul 12.

PMID:
30017245
12.

A rare case of atypical/anaplastic meningioma with MDM2 amplification.

Wylleman R, Debiec-Rychter M, Sciot R.

Rare Tumors. 2018 May 31;10:2036361318779511. doi: 10.1177/2036361318779511. eCollection 2018.

13.

Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'.

Schöffski P, Wozniak A, Stacchiotti S, Rutkowski P, Blay JY, Lindner LH, Strauss SJ, Anthoney A, Duffaud F, Richter S, Grünwald V, Leahy MG, Reichardt P, Sufliarsky J, van der Graaf WT, Sciot R, Debiec-Rychter M, van Cann T, Marréaud S, Lia M, Raveloarivahy T, Collette L, Bauer S.

Ann Oncol. 2019 Feb 1;30(2):344. doi: 10.1093/annonc/mdx823. No abstract available.

14.

Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial.

Schöffski P, Sufliarsky J, Gelderblom H, Blay JY, Strauss SJ, Stacchiotti S, Rutkowski P, Lindner LH, Leahy MG, Italiano A, Isambert N, Debiec-Rychter M, Sciot R, Van Cann T, Marréaud S, Nzokirantevye A, Collette S, Wozniak A.

Lancet Respir Med. 2018 Jun;6(6):431-441. doi: 10.1016/S2213-2600(18)30116-4. Epub 2018 Apr 15.

PMID:
29669701
15.

The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 'CREATE'.

Schöffski P, Wozniak A, Leahy MG, Aamdal S, Rutkowski P, Bauer S, Richter S, Grünwald V, Debiec-Rychter M, Sciot R, Geoerger B, Marréaud S, Collette S, Nzokirantevye A, Strauss SJ.

Eur J Cancer. 2018 May;94:156-167. doi: 10.1016/j.ejca.2018.02.011. Epub 2018 Mar 20.

PMID:
29567632
16.

Retrospective Analysis of Outcome of Patients with Metastatic Leiomyosarcoma in a Tertiary Referral Center.

van Cann T, Cornillie J, Wozniak A, Debiec-Rychter M, Sciot R, Hompes D, Vergote I, Schöffski P.

Oncol Res Treat. 2018;41(4):206-213. doi: 10.1159/000486419. Epub 2018 Mar 23.

17.

Gene expression profiling of low-grade endometrial stromal sarcoma indicates fusion protein-mediated activation of the Wnt signaling pathway.

Przybyl J, Kidzinski L, Hastie T, Debiec-Rychter M, Nusse R, van de Rijn M.

Gynecol Oncol. 2018 May;149(2):388-393. doi: 10.1016/j.ygyno.2018.03.007. Epub 2018 Mar 12.

PMID:
29544705
18.

Combination Approach for Detecting Different Types of Alterations in Circulating Tumor DNA in Leiomyosarcoma.

Przybyl J, Chabon JJ, Spans L, Ganjoo KN, Vennam S, Newman AM, Forgó E, Varma S, Zhu S, Debiec-Rychter M, Alizadeh AA, Diehn M, van de Rijn M.

Clin Cancer Res. 2018 Jun 1;24(11):2688-2699. doi: 10.1158/1078-0432.CCR-17-3704. Epub 2018 Feb 20.

19.

Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'.

Schöffski P, Wozniak A, Kasper B, Aamdal S, Leahy MG, Rutkowski P, Bauer S, Gelderblom H, Italiano A, Lindner LH, Hennig I, Strauss S, Zakotnik B, Anthoney A, Albiges L, Blay JY, Reichardt P, Sufliarsky J, van der Graaf WTA, Debiec-Rychter M, Sciot R, Van Cann T, Marréaud S, Raveloarivahy T, Collette S, Stacchiotti S.

Ann Oncol. 2018 Mar 1;29(3):758-765. doi: 10.1093/annonc/mdx774.

PMID:
29216400
20.

BCOR Internal Tandem Duplication in High-grade Uterine Sarcomas.

Mariño-Enriquez A, Lauria A, Przybyl J, Ng TL, Kowalewska M, Debiec-Rychter M, Ganesan R, Sumathi V, George S, McCluggage WG, Nucci MR, Lee CH, Fletcher JA.

Am J Surg Pathol. 2018 Mar;42(3):335-341. doi: 10.1097/PAS.0000000000000993.

PMID:
29200103
21.

Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial.

Schöffski P, Wozniak A, Escudier B, Rutkowski P, Anthoney A, Bauer S, Sufliarsky J, van Herpen C, Lindner LH, Grünwald V, Zakotnik B, Lerut E, Debiec-Rychter M, Marréaud S, Lia M, Raveloarivahy T, Collette S, Albiges L.

Eur J Cancer. 2017 Dec;87:147-163. doi: 10.1016/j.ejca.2017.10.014. Epub 2017 Nov 14.

PMID:
29149761
22.

Primary myxoid mesenchymal tumour with intracranial location: report of a case with a EWSR1-ATF1 fusion.

Sciot R, Jacobs S, Calenbergh FV, Demaerel P, Wozniak A, Debiec-Rychter M.

Histopathology. 2018 Apr;72(5):880-883. doi: 10.1111/his.13437. Epub 2018 Jan 11. No abstract available.

PMID:
29143432
23.

New targets and therapies for gastrointestinal stromal tumors.

Wozniak A, Gebreyohannes YK, Debiec-Rychter M, Schöffski P.

Expert Rev Anticancer Ther. 2017 Dec;17(12):1117-1129. doi: 10.1080/14737140.2017.1400386. Review.

PMID:
29110548
24.

Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'.

Schöffski P, Wozniak A, Stacchiotti S, Rutkowski P, Blay JY, Lindner LH, Strauss SJ, Anthoney A, Duffaud F, Richter S, Grünwald V, Leahy MG, Reichardt P, Sufliarsky J, van der Graaf WT, Sciot R, Debiec-Rychter M, van Cann T, Marréaud S, Lia M, Raveloarivahy T, Collette L, Bauer S.

Ann Oncol. 2017 Dec 1;28(12):3000-3008. doi: 10.1093/annonc/mdx527. Erratum in: Ann Oncol. 2019 Feb 1;30(2):344.

25.

In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets.

Arbajian E, Puls F, Antonescu CR, Amary F, Sciot R, Debiec-Rychter M, Sumathi VP, Järås M, Magnusson L, Nilsson J, Hofvander J, Mertens F.

Clin Cancer Res. 2017 Dec 1;23(23):7426-7434. doi: 10.1158/1078-0432.CCR-17-1856. Epub 2017 Sep 22.

26.

Macrophage infiltration and genetic landscape of undifferentiated uterine sarcomas.

Przybyl J, Kowalewska M, Quattrone A, Dewaele B, Vanspauwen V, Varma S, Vennam S, Newman AM, Swierniak M, Bakuła-Zalewska E, Siedlecki JA, Bidzinski M, Cools J, van de Rijn M, Debiec-Rychter M.

JCI Insight. 2017 Jun 2;2(11). pii: 94033. doi: 10.1172/jci.insight.94033. eCollection 2017 Jun 2.

27.

A novel EWS-CREB3L3 gene fusion in a mesenteric sclerosing epithelioid fibrosarcoma.

Dewaele B, Libbrecht L, Levy G, Brichard B, Vanspauwen V, Sciot R, Debiec-Rychter M.

Genes Chromosomes Cancer. 2017 Sep;56(9):695-699. doi: 10.1002/gcc.22474. Epub 2017 Jul 1.

PMID:
28569045
28.

In Vivo Antitumoral Efficacy of PhAc-ALGP-Doxorubicin, an Enzyme-Activated Doxorubicin Prodrug, in Patient-Derived Soft Tissue Sarcoma Xenograft Models.

Cornillie J, Wozniak A, Pokreisz P, Casazza A, Vreys L, Wellens J, Vanleeuw U, Gebreyohannes YK, Debiec-Rychter M, Sciot R, Hompes D, Schöffski P.

Mol Cancer Ther. 2017 Aug;16(8):1566-1575. doi: 10.1158/1535-7163.MCT-16-0832. Epub 2017 May 31.

29.

Single-Center Experience with Intimal Sarcoma, an Ultra-Orphan, Commonly Fatal Mesenchymal Malignancy.

Van Dievel J, Sciot R, Delcroix M, Vandeweyer RO, Debiec-Rychter M, Dewaele B, Cornillie J, Van Cann T, Meyns B, Schöffski P.

Oncol Res Treat. 2017;40(6):353-359. doi: 10.1159/000476036. Epub 2017 May 12.

30.

Phalangeal chondrosarcoma: A rare presentation with an unusual biological behavior.

Strybol D, Hermans K, Degreef I, Sinnaeve F, Pans S, Debiec-Rychter M, Sciot R.

Hand Surg Rehabil. 2017 Jun;36(3):228-229. doi: 10.1016/j.hansur.2017.01.008. Epub 2017 Apr 7. No abstract available.

PMID:
28465204
31.

Long-term results of treatment of advanced dermatofibrosarcoma protuberans (DFSP) with imatinib mesylate - The impact of fibrosarcomatous transformation.

Rutkowski P, Klimczak A, Ługowska I, Jagielska B, Wągrodzki M, Dębiec-Rychter M, Pieńkowska-Grela B, Świtaj T.

Eur J Surg Oncol. 2017 Jun;43(6):1134-1141. doi: 10.1016/j.ejso.2017.03.011. Epub 2017 Mar 22.

PMID:
28365129
32.

PDGFRB gain-of-function mutations in sporadic infantile myofibromatosis.

Arts FA, Sciot R, Brichard B, Renard M, de Rocca Serra A, Dachy G, Noël LA, Velghe AI, Galant C, Debiec-Rychter M, Van Damme A, Vikkula M, Helaers R, Limaye N, Poirel HA, Demoulin JB.

Hum Mol Genet. 2017 May 15;26(10):1801-1810. doi: 10.1093/hmg/ddx081.

PMID:
28334876
33.

MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation.

Schaefer IM, Wang Y, Liang CW, Bahri N, Quattrone A, Doyle L, Mariño-Enríquez A, Lauria A, Zhu M, Debiec-Rychter M, Grunewald S, Hechtman JF, Dufresne A, Antonescu CR, Beadling C, Sicinska ET, van de Rijn M, Demetri GD, Ladanyi M, Corless CL, Heinrich MC, Raut CP, Bauer S, Fletcher JA.

Nat Commun. 2017 Mar 8;8:14674. doi: 10.1038/ncomms14674.

34.

Overcoming Cost Implications of Mutational Analysis in Patients with Gastrointestinal Stromal Tumors: A Pragmatic Approach.

Schöffski P, Wozniak A, Schöffski O, van Eycken L, Debiec-Rychter M.

Oncol Res Treat. 2016;39(12):811-816. Epub 2016 Nov 18.

35.

Cabozantinib Is Active against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different KIT Mutations.

Gebreyohannes YK, Schöffski P, Van Looy T, Wellens J, Vreys L, Cornillie J, Vanleeuw U, Aftab DT, Debiec-Rychter M, Sciot R, Wozniak A.

Mol Cancer Ther. 2016 Dec;15(12):2845-2852. Epub 2016 Oct 24.

36.

Recurrent MALAT1-GLI1 oncogenic fusion and GLI1 up-regulation define a subset of plexiform fibromyxoma.

Spans L, Fletcher CD, Antonescu CR, Rouquette A, Coindre JM, Sciot R, Debiec-Rychter M.

J Pathol. 2016 Jul;239(3):335-43. doi: 10.1002/path.4730. Epub 2016 May 20.

37.

Pulmonary metastasis of a meningioma presenting as a solitary pulmonary nodule: 2 case reports.

Leemans J, Van Calenbergh F, Sciot R, Debiec-Rychter M, Decaluwe H, Nackaerts K.

Acta Clin Belg. 2016 Apr;71(2):107-10. doi: 10.1080/17843286.2015.1133002. Epub 2016 Feb 6.

PMID:
27075807
38.

Phospholipase C gamma 1 (PLCG1) R707Q mutation is counterselected under targeted therapy in a patient with hepatic angiosarcoma.

Prenen H, Smeets D, Mazzone M, Lambrechts D, Sagaert X, Sciot R, Debiec-Rychter M.

Oncotarget. 2015 Nov 3;6(34):36418-25. doi: 10.18632/oncotarget.5503.

39.

A rare mutation in a rare tumor--SMARCB1-deficient malignant glomus tumor.

Dabek B, Kram A, Kubrak J, Kurzawski M, Wojcik P, Machnicki MM, Stoklosa T, Rydzanicz M, Ploski R, Debiec-Rychter M.

Genes Chromosomes Cancer. 2016 Jan;55(1):107-9. doi: 10.1002/gcc.22296. Epub 2015 Sep 22. No abstract available.

PMID:
26391213
40.

Lysosomal Sequestration Determines Intracellular Imatinib Levels.

Burger H, den Dekker AT, Segeletz S, Boersma AW, de Bruijn P, Debiec-Rychter M, Taguchi T, Sleijfer S, Sparreboom A, Mathijssen RH, Wiemer EA.

Mol Pharmacol. 2015 Sep;88(3):477-87. doi: 10.1124/mol.114.097451. Epub 2015 Jun 24.

PMID:
26108972
41.

Current treatment options for dermatofibrosarcoma protuberans.

Rutkowski P, Debiec-Rychter M.

Expert Rev Anticancer Ther. 2015;15(8):901-9. doi: 10.1586/14737140.2015.1052799. Epub 2015 May 31. Review.

PMID:
26027711
42.

First evidence of treatment efficacy in metastatic carcinoma of the parotid gland with BRD4/NUT translocation.

Vulsteke C, Lurquin E, Debiec-Rychter M, Gheysens O, Nuyts S, Schoenaers J, Politis C, Mebis J, Hauben E, Clement PM.

J Chemother. 2016 Jun;28(3):242-6. doi: 10.1179/1973947815Y.0000000046.

PMID:
26027633
43.

Therapeutic Efficacy Assessment of CK6, a Monoclonal KIT Antibody, in a Panel of Gastrointestinal Stromal Tumor Xenograft Models.

Van Looy T, Wozniak A, Floris G, Li H, Wellens J, Vanleeuw U, Sciot R, Debiec-Rychter M, Schöffski P.

Transl Oncol. 2015 Apr;8(2):112-8. doi: 10.1016/j.tranon.2015.02.004.

44.

Angiomatoid fibrous histiocytoma - case series with emphasis on a late fibrotic variant.

Wilk M, Zelger BG, Debiec-Rychter M, Sciot R, Zelger B.

J Dtsch Dermatol Ges. 2015 May;13(5):441-8. doi: 10.1111/ddg.12600.

PMID:
25918088
45.

Mammary analogue secretory carcinoma of the sinus ethmoidalis.

Lurquin E, Jorissen M, Debiec-Rychter M, Hermans R, Hauben E.

Histopathology. 2015 Nov;67(5):749-51. doi: 10.1111/his.12702. Epub 2015 May 12. No abstract available.

PMID:
25828788
46.

Guidelines for cytogenetic investigations in tumours.

Hastings RJ, Bown N, Tibiletti MG, Debiec-Rychter M, Vanni R, Espinet B, van Roy N, Roberts P, van den Berg-de-Ruiter E, Bernheim A, Schoumans J, Chatters S, Zemanova Z, Stevens-Kroef M, Simons A, Heim S, Salido M, Ylstra B, Betts DR; Tumour Best Practice meeting; Eurogentest.

Eur J Hum Genet. 2016 Jan;24(1):6-13. doi: 10.1038/ejhg.2015.35. Epub 2015 Mar 25. No abstract available.

47.

Co-segregation of Freiberg's infraction with a familial translocation t(5;7)(p13.3;p22.2) ascertained by a child with cri du chat syndrome and brachydactyly type A1B.

Myśliwiec M, Panasiuk B, Dębiec-Rychter M, Iwanowski PS, Łebkowska U, Nowakowska B, Marcinkowska A, Stankiewicz P, Midro AT.

Am J Med Genet A. 2015 Feb;167A(2):445-9.

PMID:
25756154
48.

Lack of Evidence That Male Fetal Microchimerism is Present in Endometriosis.

Fassbender A, Debiec-Rychter M, Van Bree R, Vermeesch JR, Meuleman C, Tomassetti C, Peeraer K, D'Hooghe T, Lebovic DI.

Reprod Sci. 2015 Sep;22(9):1115-21. doi: 10.1177/1933719115574343. Epub 2015 Mar 5.

49.

Pazopanib, a Receptor Tyrosine Kinase Inhibitor, Suppresses Tumor Growth through Angiogenesis in Dedifferentiated Liposarcoma Xenograft Models.

Li H, Wozniak A, Sciot R, Cornillie J, Wellens J, Van Looy T, Vanleeuw U, Stas M, Hompes D, Debiec-Rychter M, Schöffski P.

Transl Oncol. 2014 Dec;7(6):665-71. doi: 10.1016/j.tranon.2014.09.007.

50.

Genomic index predicts clinical outcome of intermediate-risk gastrointestinal stromal tumours, providing a new inclusion criterion for imatinib adjuvant therapy.

Lartigue L, Neuville A, Lagarde P, Brulard C, Rutkowski P, Dei Tos P, Wardelmann E, Debiec-Rychter M, Italiano A, Coindre JM, Chibon F.

Eur J Cancer. 2015 Jan;51(1):75-83. doi: 10.1016/j.ejca.2014.10.014. Epub 2014 Nov 6.

PMID:
25466504

Supplemental Content

Loading ...
Support Center